GLS Pharma Ltd

Exemestane is the latest in the family of aromatase inhibitors which provide the convenience of long-term oral therapy in a large sub-group of breast cancer patients.

Exemestane is the latest in the family of aromatase inhibitors which provide the convenience of long-term oral therapy in a large sub-group of breast cancer patients.

Indications:

• For adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy

• For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy